Search

Search Constraints

You searched for: Author/Creator Minar, Lubos

Search Results

1. 2022-RA-1304-ESGO Molecular testing of endometrial carcinoma brings growing opportunity to identify patients with inherited risk of cancer. (20th October 2022)

2. 2022-RA-959-ESGO Pelvic sentinel lymph nodedistribution; the final outcome of the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063). (20th October 2022)

3. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. Issue 3 (1st March 2018)

4. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. Issue 3 (March 2018)

8. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Issue 1 (6th January 2022)

10. Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial. (September 2020)